These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 1979657)
21. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848 [TBL] [Abstract][Full Text] [Related]
22. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group. Wolters EC; Horstink MW; Roos RA; Jansen EN Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204 [No Abstract] [Full Text] [Related]
23. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
24. Experiences with Sinemet CR in the Paracelsus-Elena-Klinik. Ulm G; Gerdes U; Haagen K Neurology; 1989 Nov; 39(11 Suppl 2):85-7; discussion 95. PubMed ID: 2586768 [TBL] [Abstract][Full Text] [Related]
26. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Deleu D; Jacques M; Michotte Y; Ebinger G Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654 [TBL] [Abstract][Full Text] [Related]
27. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa. LeWitt PA Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198 [TBL] [Abstract][Full Text] [Related]
28. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604 [TBL] [Abstract][Full Text] [Related]
29. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Cedarbaum JM; Kutt H; McDowell FH Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762 [TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease. Mark MH; Sage JI Ann Clin Lab Sci; 1989; 19(6):415-21. PubMed ID: 2690730 [TBL] [Abstract][Full Text] [Related]
37. Sinemet CR in Parkinson's disease. Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878 [TBL] [Abstract][Full Text] [Related]
38. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590 [TBL] [Abstract][Full Text] [Related]
39. Sinemet CR for Parkinson's disease. Med Lett Drugs Ther; 1991 Oct; 33(854):92-3. PubMed ID: 1895993 [No Abstract] [Full Text] [Related]
40. Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa. Ahlskog JE; Muenter MD; Bailey PA; Miller PM Clin Neuropharmacol; 1991 Jun; 14(3):214-27. PubMed ID: 1676932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]